JPRN-jRCT2080224105
Completed
Phase 3
Phase III study for evaluating efficacy and safety of a combination treatment of IDEC-C2B8 with steroid pulse therapy and plasmapheresis for antibody-mediated rejection after kidney transplant.
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ZENYAKU KOGYO CO., LTD.
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patients who develop or suspect ABMR requiring treatment with IDEC\-C2B8\.
- •2\.Patients who are 16 years and over at giving written informed consent.
- •3\.Patients or Patient's representative who are able to understand the study protocol and provide the written informed consent.
Exclusion Criteria
- •1\.Patients who have a history of hypersensitivity or severe allergic to murine products.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Phase III study for evaluating efficacy and safety of desensitization based on IDEC-C2B8 in living donor kidney transplantation recipients with pre-formed anti-HLA antibody and/or donor-specific antibody. Phase III study for evaluating efficacy, safety and pharmacokinetics of pre-transplant administration of FK506 or FK506E(MR4) for 7 to 28 days in living donor kidney transplantation recipients.iving donor kidney transplantation recipients with pre-formed anti-HLA antibody and/or donor-specific antibody.JPRN-jRCT2080224107ZENYAKU KOGYO CO., LTD.23
Active, not recruiting
Phase 1
A study to assess the efficacy and safety of Dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine A (CSA) or for those who cannot take oral CSA because it is not medically advisableAtopic dermatitisMedDRA version: 18.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2015-002653-35-IERegeneron Pharmaceuticals, Inc.330
Active, not recruiting
Phase 1
A study to assess the efficacy and safety of Dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine A (CSA) or for those who cannot take oral CSA because it is not medically advisableEUCTR2015-002653-35-NLRegeneron Pharmaceuticals, Inc.330
Active, not recruiting
Phase 1
A study to assess the efficacy and safety of Dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine A (CSA) or for those who cannot take oral CSA because it is not medically advisableAtopic dermatitisMedDRA version: 19.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2015-002653-35-BERegeneron Pharmaceuticals, Inc.330
Active, not recruiting
Phase 1
A study to assess the efficacy and safety of Dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine A (CSA) or for those who cannot take oral CSA because it is not medically advisableAtopic dermatitisMedDRA version: 19.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2015-002653-35-ESRegeneron Pharmaceuticals, Inc.330